Trial · NCT03003143
Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients
NCT03003143, Not applicable, Withdrawn, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients. Trials, record NCT03003143. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03003143
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients
- NCT number
- NCT03003143
- Status
- Withdrawn
- Phases
- Not applicable
- Enrollment
- 0 participants, actual
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Autoimmune Encephalopathy
- Interventions
- Vigabatrin 500 MG
- First posted
- 2016-12-26
- Last updated
- 2021-09-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seizure frequency reduction | 3 month of vigabatrin administration | 50% reduction - favorable outcome |
| Secondary | Modified Rankin Scale | 3 month of vigabatrin administration | |
| Secondary | Quality of life (Quality of Life in Epilepsy Inventory, QOLIE-31) | after 3 month of vigabatrin administration | |
| Secondary | Depression (Beck Depression Inventory®-II) | 3 month of vigabatrin administration | |
| Secondary | Cognition (Mini-Mental State Examination-Korean) | 3 month of vigabatrin administration | |
| Secondary | Sleep quality (Pittsburgh Sleep Quality Assessment) | 3 month of vigabatrin administration |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03003143
GET https://conductscience.org/api/trials/v1/NCT03003143/registered